Insider at Solid Biosciences (NASDAQ: SLDB) to sell 10,905 shares

Rhea-AI Filing Summary

Solid Biosciences insider Paul Herzich has filed a notice under Rule 144 to sell 10,905 shares of the company’s common stock through E*TRADE on or about 02/04/2026, to be traded on NASDAQ. The aggregate market value of the planned sale is 70,246.73.

The shares to be sold were acquired the same day through settlement of vested restricted stock units as compensation from the issuer. The filing also reports that, over the past three months, Herzich sold 2,701 shares for gross proceeds of 13,802.11 and 26,250 shares for gross proceeds of 168,968.63.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	ETRADE FINANCIAL CORPORATION 3 EDISON DRIVE ALPHARETTA GA 30005	10905	70246.73	82569192	02/04/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/04/2026	Settlement of vested restricted stock units	Issuer			10905	02/04/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Herzich Paul C/O SOLID BIOSCIENCES INC. 500 Rutherford Avenue Charlestown MA 02129	Common Stock	12/03/2025	2701	13802.11
Herzich Paul C/O SOLID BIOSCIENCES INC. 500 Rutherford Avenue Charlestown MA 02129	Common Stock	02/02/2026	26250	168968.63

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the latest Form 144 filing disclose for Solid Biosciences (SLDB)?

The filing shows insider Paul Herzich plans to sell 10,905 shares of Solid Biosciences common stock under Rule 144. The planned sale, via E*TRADE on NASDAQ, has an aggregate market value reported as 70,246.73 based on the information provided.

How many Solid Biosciences (SLDB) shares is the insider planning to sell?

The insider plans to sell 10,905 shares of Solid Biosciences common stock. These shares were acquired through settlement of vested restricted stock units on 02/04/2026 and will be sold through E*TRADE on NASDAQ, with an aggregate market value listed as 70,246.73.

How were the Solid Biosciences (SLDB) shares in this Form 144 acquired?

The 10,905 Solid Biosciences shares were acquired on 02/04/2026 through settlement of vested restricted stock units. The filing describes the nature of the transaction as compensation from the issuer, rather than a cash purchase, with payment date also shown as 02/04/2026.

What prior share sales has the insider reported for Solid Biosciences (SLDB)?

Over the past three months, the insider reported selling 2,701 shares of Solid Biosciences common stock on 12/03/2025 for gross proceeds of 13,802.11, and 26,250 shares on 02/02/2026 for gross proceeds of 168,968.63, according to the disclosure table.

Which broker and exchange are involved in the Solid Biosciences (SLDB) Form 144 sale?

The planned sale of 10,905 Solid Biosciences shares is listed through E*TRADE Financial Corporation as the broker. The filing specifies that the common stock will be traded on NASDAQ, with the aggregate market value for this sale reported as 70,246.73.

How many Solid Biosciences (SLDB) shares are shown as outstanding in the Form 144?

The Form 144 indicates 82,569,192 shares of Solid Biosciences common stock outstanding. This figure is presented in the securities information table as a baseline for the class of securities, separate from the 10,905 shares covered by the planned Rule 144 sale.